GleamWall
中文EN

EWTX Edgewise Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1710072 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY742.1%
TTM EPS YoY633.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE92.1%
ROA85.4%
ROIC (approx.)-16.6%
Asset turnover—

Leverage & solvency

Liabilities / assets8.3%
Debt / equity0.00x
Current ratio12.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.20x
Accruals ratio102.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$31.57M$47.55M$42.65M$43.59M$37.48M$33.56M$36.76M$36.37M
SG&A expense$14.57M$14.39M$11.46M$12.38M$9.38M$9.05M$9.20M$9.17M
Operating income-$46.14M-$61.94M-$54.12M-$55.98M-$46.86M-$42.61M-$45.96M-$45.54M
Pretax income$1.32B——-$50.22M-$40.67M———
Income tax$155.33M———————
Net income$1.17B-$57.33M-$49.01M-$50.22M-$40.67M-$36.12M-$40.80M-$39.66M
EBITDA-$45.64M-$61.44M-$53.58M-$55.45M-$46.36M-$42.11M-$45.45M-$44.96M
EPS (basic)10.71-0.53-0.46—-0.39-0.34-0.43—
EPS (diluted)9.65-0.53-0.46—-0.39-0.34-0.43—
Weighted avg. shares (diluted)120.87M107.67M107.12M—105.49M104.94M95.13M—
Balance sheet
Cash & equivalents$68.68M$72.32M$33.21M$61.15M$46.00M$43.40M$49.92M$41.67M
Current assets$1.77B$471.52M$509.79M$543.38M$573.90M$603.25M$443.18M$475.48M
PP&E, net$6.33M$6.89M$7.40M$7.83M$8.13M$8.60M$8.99M$9.50M
Total assets$1.78B$479.69M$518.52M$552.60M$583.47M$613.33M$454.39M$486.82M
Current liabilities$144.11M$29.04M$22.54M$27.37M$21.65M$20.90M$21.11M$23.86M
Total liabilities$147.35M$31.61M$25.32M$30.35M$24.82M$24.26M$24.67M$27.60M
Shareholders' equity$1.63B$448.08M$493.20M$522.26M$558.65M$589.07M$429.72M$459.22M
Shares outstanding109.46M107.78M107.48M106.25M105.76M105.34M95.21M94.84M
Cash flow statement
Operating cash flow-$78.29M-$42.47M-$42.54M-$38.59M-$34.78M-$32.58M-$37.87M-$26.96M
Capital expenditure$17,000$32,000$260,000$73,000$89,000$50,000$44,000$274,000
Free cash flow-$78.31M-$42.50M-$42.80M-$38.66M-$34.87M-$32.63M-$37.91M-$27.23M
Investing cash flow$59.67M$78.49M$2.43M$49.76M$35.72M-$162.17M$43.90M$20.92M
Financing cash flow$14.98M$3.09M$12.17M$3.98M$1.66M$188.23M$2.22M$2.90M
Depreciation & amortization$500,000$500,000$537,000$525,000$500,000$500,000$513,000$577,000
Stock-based compensation$8.56M$9.36M$8.71M$9.88M$8.09M$7.73M$9.06M$7.74M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.